Niosomal drug delivery systems for ocular disease-recent advances and future prospects
Open accessThe DOI matches its Crossref record; 124 of the 126 references it cites were found in a registry or an index.
Abstract
The eye is a complex organ consisting of several protective barriers and particular defense mechanisms. Since this organ is exposed to various infections, genetic disorders, and visual impairments it is essential to provide necessary drugs through the appropriate delivery routes and vehicles. The topical route of administration, as the most commonly used approach, maybe inefficient due to low drug bioavailability. New generation safe, effective, and targeted drug delivery systems based on nanocarriers have the capability to circumvent limitations associated with the complex anatomy of the eye. Nanotechnology, through various nanoparticles like niosomes, liposomes, micelles, dendrimers, and different polymeric vesicles play an active role in ophthalmology and ocular drug delivery systems. Niosomes, which are nano-vesicles composed of non-ionic surfactants, are emerging nanocarriers in drug delivery applications due to their solution/storage stability and cost-effectiveness. Additionally, they are biocompatible, biodegradable, flexible in structure, and suitable for loading both hydrophobic and hydrophilic drugs. These characteristics make niosomes promising nanocarriers in the treatment of ocular diseases. Hereby, we review niosome based drug delivery approaches in ophthalmology starting with different preparation methods of niosomes, drug loading/release mechanisms, characterization techniques of niosome nanocarriers and eventually successful applications in the treatment of ocular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Niosomes, which are comprised of uncharged single-chain surfactant and cholesterol94,95 have also shown limited success potential as non-viral gene delivery systems96–101 due to improved transfection efficiency, biocompatibility, and cellular uptake, in addition to effects on intracellular trafficking.102”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [97]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Higuchi, T. (1963) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600521210 · Cited by 4,884
Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,832 · cited 3×
“The homogeneity of the size distribution of the particles is defined by the polydispersity index (PDI) [96].”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918 · cited 1×
“For ocular applications, particles should have narrow size distribution and small polydispersity index values as lower PDI values are better for the uptake of nanoparticles and posterior internalization [97].”
BackgroundSzoka, F., & Papahadjopoulos, D. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.9.4194 · Cited by 2,323 · cited 14×
“It has been reported that the size of SUVs are in the range of 10–100 nm, while LUVs exhibit 100–3000 nm length, and that of MLVs are greater than 5 µm.”
MethodInfluentialMüller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113 · cited 1×
“Drug molecules diffuse with passive diffusion from donor unit to buffer solution in the receiver unit [42,109].”
BackgroundTherapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080 · cited 1×
“Nanotechnology, by providing particular carriers, is advantageous in ophthalmology in providing new ways of transfer and release, extending the drug efficacy and enabling intracellular delivery [4,5].”
BackgroundNon-ionic surfactant based vesicles (niosomes) in drug delivery
Uchegbu, I. F., & Vyas, S. P. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00169-0 · Cited by 1,020 · cited 1×
“Furthermore, the capability of niosomes in enhancing the bioavailability and efficacy of drugs attracts the researchers’ attention to apply niosomal drug delivery systems in treatment of severe inflammations and diseases such as different types of cancers [15,16].”
BackgroundChallenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003 · cited 1×
“Topical eye drops are the most prevalent way of ocular therapy for the anterior part of the eye, which includes the conjunctiva, cornea, sclera, and anterior uvea [1].”
BackgroundNano-niosomes as nanoscale drug delivery systems: An illustrated review
Moghassemi, S., & Hadjizadeh, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.015 · Cited by 797 · cited 1×
“Because of the pH difference inside (lower pH) and outside (higher pH) of the niosome, the ionized drug cannot go out and is trapped inside of the vesicle [39,87].”
Background
Research works printed but not linked: 3
- More V.V. Gilhotra R.M. Nitalikar M.M. Khule P.K. Niosomal Drug Delivery-A Comprehensive Review Asian J. Pharm. 2019 12 S1159 S1164
- Lakshmi P.K. Bhaskaran S. Phase II study of topical niosomal urea gel-an adjuvant in the treatment of psoriasis Int. J. Pharm. Sci. Rev. Res. 2011 7 1 7
- Biswas G.R. Majee S.B. Niosomes in ocular drug delivery Eur. J. Pharm. Med. Res. 2017 4 813 819
Cited by
Items 101–198 of 198
Özdemir, S., & Üner, B. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02838-2 · Cited by 8
“A comprehensive review study reported that various ophthalmic niosome formulations exhibited Higuchi type release kinetics [55].”
Karuppaiah, A., Annamalai, G., Dhasaiyan, M., Manikandan, S., Jose, P. A., & Rahman, H. (2024) · Current Nanomedicine · doi:10.2174/0124681873312762241114045714 · Cited by 8
Popova, E. V., Tikhomirova, V. E., Валерьевна, Б. О., Chesnokova, N. B., Grigoriev, Y. V., Taliansky, M. E., & Kost, O. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115532 · Cited by 8
Nanocarrier-based Drug Delivery of Brinzolamide for Ocular Diseases: A Mini-Review
Maurya, R., Vikal, A., Patel, P., Narang, R. K., & Kurmi, B. D. (2024) · Current Nanomedicine · doi:10.2174/0124681873294344240408061056 · Cited by 7
Dehghani, B., Mirzaei, M., & Lohrasbi‐Nejad, A. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-024-09913-y · Cited by 8
“When the surfactants cool below their transition temperature, the hydrocarbon chains become more regular and form impermeable gels [ 49 , 50 ].”
Niosomes as a promising nanovesicular drug delivery
Bahrololoumi, S., & Nikazar, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91668-4.00011-3 · Cited by 8
Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug
Shree, D., Patra, C. N., & Sahoo, B. M. (2023) · Pharmaceutical Nanotechnology · doi:10.2174/2211738511666230816090046 · Cited by 8
Sahoo, B. N., Joshi, B., Rana, S., Rathnam, V. S. S., Sahare, T., & Joshi, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107213 · Cited by 7
Vesicular nanocarriers: An innovative targeted and sustained drug delivery system
Gomathi, R., Bharathiraja, A., Sabitha, V., Snekha, K., Susmitha, R., Gokulram, P., & Selvasudha, N. (2026) · Next Bioengineering · doi:10.1016/j.nxbio.2026.100024 · Cited by 6
Nanotechnology-based Therapeutic Strategies for Dry Eye Disease
Philip, A. K. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00034 · Cited by 6
Nanovesicles as Potential Carriers for Delivery of Antiviral Drugs: A Comprehensive Review
Bindhani, S., & Nayak, A. K. (2024) · Current Drug Delivery · doi:10.2174/0115672018313783240603114509 · Cited by 6
Spanlastics ocular delivery: a comprehensive review of formulation and therapeutic potential
Sahin, S., Sarma, S., Das, A., Baishya, B., Das, A. K., & Deka, M. K. (2025) · Discover Pharmaceutical Sciences · doi:10.1007/s44395-025-00009-1 · Cited by 8
“A promising field of study that could transform the management of numerous ocular conditions is the creation of novel nano-delivery methods for medications [39–41].”
CELECOXIB NIOSOMAL IN-SITU GEL AS A VALUABLE DRUG DELIVERY SYSTEM FOR OCULAR INFLAMMATION
Ahmed, M. F., Khalil, I. A., Hassanein, K. M. A., El-Gendy, G., & Ismail, S. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.327673 · Cited by 6
Yetisgin, A. A., Durak, S., Kutlu, Ö., & Çetinel, S. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202300531 · Cited by 6
Self-citationTargeted drug delivery: concepts, approaches, and applications
Russi, M., Marson, D., Laurini, E., & Pricl, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91816-9.00003-5 · Cited by 10
Nanostructure colloids in ocular drug delivery: advances and challenges
Khaledian, S., Abdoli, M., Mirzaee, S., & Nokhodchi, A. (2025) · Chemical Papers · doi:10.1007/s11696-025-04315-x · Cited by 5
“Until now, various drug compounds like dorzolamide, flurbiprofen, gatifloxacin, etc., have been encapsulated in niosomes for the treatment of various ocular complications (Durak et al. 2020).”
Characterization of Spanlastic System Loaded Green Tea Extract as Antioxidant for Skin
Santuso, E., Soeratri, W., & Purwanti, T. (2023) · JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA · doi:10.20473/jfiki.v10i12023.30-37 · Cited by 5
DISCOSOMES: A FUTURISTIC UPHEAVAL IN VESICULAR DRUG DELIVERY
JOSE, A. M., LAKSHMI, V. U., Gayathri, S., & Nair, S. C. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021v13i6.42008 · Cited by 5
Patel, G. K., Prajapati, B. G., & Pathak, Y. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-14100-3_12 · Cited by 5
Niosomes: A Smart Drug Carrier Synthesis, Properties and Applications
Alle, M., Samed, N., & Kim, J. (2021) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-84262-8_16 · Cited by 4
Liposome-Based Drug Delivery—A New Therapeutic Paradigm
Shetye, L. A., Sherlekar, A., & Mendhulkar, V. D. (2023) · Studies in mechanobiology, tissue engineering and biomaterials · doi:10.1007/978-981-99-6564-9_2 · Cited by 6
Zalnezhad, S., Adeli‐Sardou, M., Roostaee, M., Barani, M., Mirzaei, M., & Sargazi, G. (2024) · Journal of Surfactants and Detergents · doi:10.1002/jsde.12782 · Cited by 4
Kapse, S. J., Prakash, J., & Vivekkumar, R. (2023) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v11i4.1295 · Cited by 4
“The size of the small unilamellar vesicles has been estimated to be between 10 and 100 nm 46,47.”
BackgroundAlsarayreh, N., Abdelghany, S. M., Alqudah, D. A., Abuarqoub, D. A., & Alshaer, W. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105617 · Cited by 6
Ocular Drug Delivery Routes: Diseases Overview and Advanced Administration Methods
Yetgin, C., Tuğcu-Demiröz, F., & Takka, S. (2024) · Fabad Journal of Pharmaceutical Sciences · doi:10.55262/fabadeczacilik.1496246 · Cited by 5
“It is seen that there are many studies in the literature regarding the application of niosomes to the eyes (Abdelkader et al., 2012; Alyami, Abdelaziz, Dahmash, & Iyire, 2020; Durak et al., 2020; Zeng et al., 2016).”
BackgroundProniosomes and niosomes for enhanced drug delivery
Benedini, L. A., & Messina, P. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91864-0.00005-x · Cited by 10
Chetoni, P., Burgalassi, S., Zucchetti, E., Granchi, C., Minutolo, F., Tampucci, S., & Monti, D. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122078 · Cited by 4
Recent Strategies for Ocular Drug Delivery: Promises and Challenges
El-Kamel, A. H., & Ashour, A. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106335 · Cited by 7
Ugorji, O. L., Okoye, O. I., Nwangwu, C., Agbo, C. P., & Kenechukwu, F. C. (2023) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2023.2186427 · Cited by 4
Functionalized liposomes and niosomes for cancer therapy
Yavari, M., Foroushani, E. S., Nasri, N., Zarepour, A., Zarrabi, A., & Mostafavi, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00028-8 · Cited by 4
Self-citationGuo, Z., Song, Y., Liu, Z., Dai, J., Chen, Z., Feng, X., Gao, W., Zeng, L., & Hong-tao, S. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01726-3 · Cited by 3
Su, G., & Xu, W. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s577320 · Cited by 3
“20 Dendrimers, on the other hand, are branched macromolecules that can be engineered to possess specific surface functionalities, enhancing their interaction with target cells and improving drug solubility.”
Zhao, D., Wang, C., Jiang, Z., Xu, Y., Xia, Y., Zhang, P., & Ye, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1809139 · Cited by 3
“Niosomes (non-ionic surfactant vesicles) enhance transcellular permeability via fusion with cell membranes or endocytosis, though enzymatic digestion of the blood-retinal barrier may be required for optimal macromolecular delivery (Durak et al., 2020).”
Alali, U., Al-Tu’ma, M. M. K., Jawad, A. F., Ahmed, S. T., Ali, H. A., Abdulzehra, S., & Al-Tu’ma, F. J. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.7.2539 · Cited by 3
“Based on the previous studies, it is evident that niosomes exhibit a spherical morphology [55].”
BackgroundAki, D., Rad, M. E., Şenel, E. C., Onceyiz, M. C., Gokmenoglu, M. C., Duta, L., & Gunduz, O. (2025) · Biomedical Materials · doi:10.1088/1748-605x/ade8c7 · Cited by 3
Chitosan Nanoparticles: The Drug Delivery System to the Anterior Segment of the Eye
Popova, E. V., Tikhomirova, V. E., Валерьевна, Б. О., Chesnokova, N. B., Grigoriev, Y. V., & Kost, O. A. (2023) · Moscow University Chemistry Bulletin · doi:10.3103/s0027131423020062 · Cited by 3
Norozipor, S., Bamorovat, M., Mousavi, S. A. A., Salarkia, E., Hadizadeh, S., Sharifi, F., Karamoozian, A., Ranjbar, M., & Afshari, S. A. K. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101478 · Cited by 4
Paul, P., Veerabomma, H., Gupta, U., Atram, D., Singh, P. K., Mehra, N. K., Godugu, C., Baldi, A., & Madan, J. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105666 · Cited by 5
Obeaid, N. G., Al-Tu’ma, F. J., & Majeed, A. M. K. (2024) · Journal of Cluster Science · doi:10.1007/s10876-024-02667-0 · Cited by 4
“Niosome formulations also have been observed to exhibit higher entrapment efficiency compared to other NPs, leading to extended drug release over time [ 53 ].”
Shirin, N. J., Gharaghie, T. P., Beiranvand, S., Riahi, A., & Fattahi, N. (2021) · Research Square · doi:10.21203/rs.3.rs-191656/v1 · Cited by 3
Nanotherapeutics in cancer-associated infections
Singh, R., Dheek, M., Chauhan, S. B., & Singh, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28836-4.00023-8 · Cited by 2
Yetisgin, A. A., Kutlu, Ö., & Çetinel, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107156 · Cited by 2
Altaee, M., Faheem, A., & Elkordy, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070862 · Cited by 2
“Niosomes can be optimised to become a multi-route drug delivery system, where they can be administered orally [5], parenterally [6], topically [7], ocularly [8] and via other routes.”
Durak, S., Yetisgin, A. A., Açıksarı, A., Ceylan, R., Tokuç, E. Ö., Kutlu, Ö., Karabas, V. L., & Çetinel, S. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.202500263 · Cited by 2
“…from a polymeric system and the amount of drug released against time is established by Korsmeyer-Peppas equation [ 69 ], where Mt/M ∞ is a fraction of drug released in time t, K is the release constant, and n is the release diffusion coefficient, which indicates the release mechanism [ 69 ].”
Self-citationShivgotra, R., Soni, B., Bakrey, H., Kaur, P., & Jain, S. K. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03368-9 · Cited by 2
“Recent studies have examined their ability to improve the distribution of various drugs in ocular therapy [97, 98].”
Rahma, S., Amalia, E., & Kusuma, S. A. F. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s607567 · Cited by 2
“82,83 Mechanistically, surfactant HLB regulates bilayer packing density and membrane phase behavior.”
InfluentialCHITOSAN NANOPARTICLES - THE DRUG DELIVERY SYSTEM TO THE ANTERIOR SEGMENT OF THE EYE
Popova, E. V., Tikhomirova, V. E., Валерьевна, Б. О., Chesnokova, N. B., Grigoriev, Y. V., & Kost, O. A. (2023) · Lomonosov chemistry journal · doi:10.55959/msu0579-9384-2-2023-64-2-141-151 · Cited by 2
Kumari, P., Gupta, U. C., & Goyal, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-819979-4.00008-8 · Cited by 2
The efficacy of niosomal antifungal drug delivery system for Candida infections: a literature review
Norozipuor, S., & Afshari, S. A. K. (2024) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000399 · Cited by 3
Advances and Opportunities of the Novel Functional Nanocarriers
Manchanda, N., Pathak, S., Srivastava, D., Mittal, S., & Talegaonkar, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-6306-4_9 · Cited by 3
Nanotechnology: Reviewing the New Concept of Drug Delivery
Ansari, M. H., & Yadav, S. S. (2023) · International Journal of Medical & Pharmaceutical Sciences · doi:10.31782/ijmps.2023.13101 · Cited by 2
The Niosomes: An Overview In Ocular Drug Delivery System As An Advanced Approach
Singh, D., Savita, K. K., Mishra, A. K., Mishra, K., & Shakya, D. (2023) · Journal for ReAttach Therapy and Developmental Diversities · doi:10.53555/jrtdd.v6i10s.2685 · Cited by 2
Pal, R., Pandey, P., Khadam, V. K. R., Chawra, H. S., & Singh, R. P. (2024) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.69580/ijppr.15.2.2024.1-18 · Cited by 2
Targeted delivery strategies for nanomedicine
Hiwrale, A., Patil, A., Pingale, P., & Rajput, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21507-0.00015-5 · Cited by 1
An overview of novel formulations for ocular viral infections: focused on nanomedicines
Verma, S., Nainwal, N., & Juyal, D. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2515998 · Cited by 1
“[ 60].”
PRONIOSOMES: A NOVEL VESICULAR CARRIER FOR OCULAR DRUG TARGETING
RATHORE, A. S., Verma, S., AGGARWAL, K., & Singh, A. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i7.54552 · Cited by 1
Niosomes as versatile nanocarriers in diabetes research
Rathi, D.-N. G., Norman, A., Esa, N. M., & Abdullah, C. A. C. (2025) · International Journal of Materials Research (formerly Zeitschrift fuer Metallkunde) · doi:10.1515/ijmr-2024-0270 · Cited by 1
Kanugo, A., & Teli, N. (2025) · Current Drug Delivery · doi:10.2174/0115672018383855251007175252 · Cited by 2
Quality by design in ophthalmic product development
Sharma, S., Soni, M. L., Pathan, H. K., & Sharma, R. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33781-9.00009-5 · Cited by 1
Unleashing the Potential of Cubosomes to Overcome Ocular Barriers in Precision Drug Delivery
Narula, H., Devi, N., Singh, T. G., Kumar, P., Dhiman, S., & Dora, C. P. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500267 · Cited by 1
“To overcome these challenges, there has been an increasing focus on novel drug delivery systems such as nanoparticles, liposomes, hydrogels, nanoemulsions, niosomes, micelles, and dendrimers [31].”
Balasubramani, K., Arthanari, S., Subramanian, M., & Mohan, P. (2025) · Next Nanotechnology · doi:10.1016/j.nxnano.2025.100321 · Cited by 1
Nanovesicular Drug Delivery Systems for Overcoming Antibiotic Resistance
Pillai, G., & Jankie, S. (2025) · Cureus · doi:10.7759/cureus.98926 · Cited by 2
“To circumvent these challenges, newer ocular delivery systems are being investigated [83,84], such as niosomal formulations of gentamicin [85].”
Recent advances in smart contact lenses
Adibag, Z., Ghanbarzadeh, M., Salati, M. A., Rad, M. E., Ansari, R., Ta, C. N., Fadel, D., Mofidfar, M., & Abbasi, F. (2025) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2025.100734 · Cited by 1
Niosomes in nanofibers for ocular delivery of nimodipine
Marouf, M. A., Arafa, M. F., Kenawy, E., Edries, T. B., & Maghraby, G. M. E. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108129 · Cited by 2
Ocular drug delivery in the era of nanomedicine, gene therapy, and digital twins
Choudhary, K., Kumar, A., Kumar, M., Patel, P., & Kurmi, B. D. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108318 · Cited by 1
Bioconjugated materials: Preparation, characterization and therapeutic applications
(2023) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2023.02.001 · Cited by 1
Indalifiany, A., Suryani, S., Aspadiah, V., Mahmudah, R., & Annisa, R. (2023) · Jurnal Sains dan Kesehatan · doi:10.30872/jsk.v5i5.566 · Cited by 1
Nanovesicles for ocular drug delivery
Antimisiaris, S. G., & Natsaridis, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91865-7.00025-0
(2022) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2023/12.1.6748
Thymoquinone in Cancers Therapy
Almajali, B., Al-wajeeh, A. S., & Al‐Jamal, H. A. N. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/up.1.22.31
Emerging Trends of Ocular Drug Delivery
Yasri, S., & Wiwanitkit, V. (2023) · Wiley eBooks · doi:10.1002/9781394167708.ch18 · Cited by 1
Naseroleslami, M., & Mohseni, M. M. (2024) · ̒Ulūm va funūn-i bastah/bandī · doi:10.61186/ibj.3994 · Cited by 1
“On the other hand, studies have shown that the controlled release of bioactive molecules has significant therapeutic advantage [12,13,34] .”
BackgroundResultNiosomal-Loaded Buccal Films: A Potential System for Oral Mucosal Drug Delivery
Naringe, N. D., Sarkar, D. R., Dhapke, P. R., Padole, N., Dhoble, N. N., & Baheti, J. (2025) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2025.00004
Anterior Segment Drug Delivery
Ngo, W., Phan, C., & Hui, A. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781839169779-00311
Eyes on the Future: Nano-medicine Innovations in Enhancing Ocular Bioavailability
Virmani, T., Kumar, G., Jain, P., Virmani, R., Sharma, A., Gugulothu, D. B., Akhtar, M. S., Afzal, O., Farooqui, S., Singh, A. P., et al. (2025) · BioNanoScience · doi:10.1007/s12668-025-02222-9
“They do this by dissolving junctional complexes and breaking down the mucus layer [32].”
Niosome: A Comprehensive Review of Development, Characterization and Applications
Kumar, L., Mercy, O. I., Nayana, D. N., Shreya, K., Sumeer, J. B. U., Devi, V. K., Joshi, V. G., Lakshmi, C. S., Bukka, R., Nargund, R. R., et al. (2026) · Asian Journal of Pharmacy and Technology · doi:10.52711/2231-5713.2026.00008
Early Observations and Empirical Knowledge
Ledwaba, M., & Chabalala, M. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-10618-6_1
Advancing cancer therapeutics: MicroRNA delivery via nano-niosomes
Kaur, A. P., Bhuker, S., Saini, A. K., & Saini, R. V. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108198 · Cited by 1
Cellular lipids: fundamental host factors for monkeypox virus replication and pathogenesis
Nawrooz, M. S., Taher, W. M., Alwan, M., Jawad, M. J., Mushtaq, H., & Allela, O. Q. B. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04834-5
“…and cost-effectiveness through affordable manufacturing and stable storage, limit systemic toxicity by minimizing the off-target effects of cholesterol depletion on immune func - tion, and enable sustained drug release at lesion sites (Durak et al. 2020; Salem et al. 2021; Yasamineh et al. 2022).”
Yildirim, Ö. Ç. (2026) · Türk doğa ve fen dergisi :/Türk doğa ve fen dergisi · doi:10.46810/tdfd.1623422
Goyal, S., & Vanita, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43986-5.00042-4
Chaudhari, P., Shaji, A. K., Lewis, S. A., Prasad, S., Priyanka, & Kour, A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108331
Sankula, K. R., Kunam, V., Prathibha, C. V., Shaikh, W. A. G., Sharma, B., Bharathi, D., Patil, P. M., & Waghmare, N. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.13s.46
Development of the analitical model in bioprinting of soft materials in ophtalmology
Nježić, S. (2025) · National Repository of Dissertations in Serbia
Chemistry of Ophthalmic Preparations: Proper Use, Formulation Errors and Recent Advances
Oruç, Y. (2026) · International Journal of Chemistry and Technology · doi:10.32571/ijct.1886422
Advances in nanomedicine for ocular inflammatory diseases
Xiang, D., Feng, X., & Zhang, J. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.102965 · Cited by 1
PEGylated synthetic surfactant vesicles (niosomes): Overcoming the challenges of drug delivery
Saraf, S., Gautam, L., Kumari, P., Vishwakarma, N., & Rathore, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44119-6.00021-5
Somashekhar, B. G. K., Nagarajnaik, S., Thippeswamy, M., Gangiah, S., Ramesha, A. G., Hadapada, L., Sriramareddy, Y., & Madappan, D. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10814-5
“Actually, charged particles repel one another and achieve more stable structures [89].”
Fabrication of Curcumin-loaded Olaminosomes for Intracorneal Permeation Enhancement
Rani, M., Mazumder, R., Rani, A., & Mishra, R. (2026) · Journal of Natural Remedies · doi:10.18311/jnr/2026/55712
“Niosomal Formulations for Psoriasis: Enhancing Drug Delivery and Therapeutic Outcomes”
Jadhav, P. A., Sandeep, D. S., More, V. V., Maniyar, M. G., & Khule, P. K. (2026) · Proceedings in Technology Transfer · doi:10.1007/978-3-032-13768-5_81
Khodaverdi, K., Naghib, S. M., Takdehghan, G., & Sharifianjazi, F. (2026) · BioNanoScience · doi:10.1007/s12668-026-02832-x
Kanawade, S. N., Pawar, H. R., Patel, S. G., Pawde, P. S., Laware, R. B., Vikhe, D. R., & Kunkulol, R. R. (2026) · International Ophthalmology · doi:10.1007/s10792-026-04258-6
“…an EE% of 81.62 ± 1.14%, vesicle size of 248.4 ± 6.18 nm, PDI of 0.288 ± 0.013, and zeta potential of − 33.2 ± 1.62 mV (Table 7), values that were comparable to or better than proniosomal systems reported for ocular delivery of low permeable drugs including ketoconazole or brimonidine [44, 45].”
InfluentialAshrafi, F., Majdabadi, M., Moulavi, P., Asadi, S., Jozaie, S., & Shokri, H. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2730081
Cuello-Rodríguez, S., Sanna, M., Lecoeuche, I., Sarmento, B., Otero-Espinar, F. J., & Díaz-Tomé, V. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091182
“On the other hand, the loading capacity for highly hydrophilic drugs may be limited, hindering the drug’s reach to the posterior regions of the eye when applied topically and potentially requiring controlled storage conditions [222].”
Ashrafi, F., Khalili, G., Moulavi, P., Jafari, M., Asadi, S., Jozaie, S., & Jafari, R. (2026) · Journal of Microencapsulation · doi:10.1080/02652048.2026.2731041
“…hydrophilic and hydrophobic compounds while offering favourable physicochemical stability and relatively simple preparation (Yeo et al. 2018, Durak et al. 2020). their bilayer structure can moderate drug diffusion and provide a more controlled release profile, which is particularly relevant…”
Sahraei, N., Faraj, A. M., Molaei, F., & Barzegar, A. (2026) · Nano Select · doi:10.1002/nano.70189
Karampour, N. S., Dolati, P., Salim, A., Baghbadorani, M. A., Keykhaee, M., Handali, S., & Moghimipour, E. (2026) · PLoS ONE · doi:10.1371/journal.pone.0362096
Metadata
- Authors
- Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., & Zarrabi, A.
- Affiliations
- Sabancı Üniversitesi (TR)
- Nanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul 34956, Turkey
- Corresponding author
- Zarrabi, Ali
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2020-06-18
- Volume
- 10
- Issue
- 6
- Pages
- 1191
- ISSN
- 2079-4991 (ISSN-L)
- PMC
- PMC7353242
- OpenAlex
- W3036547471
- Cited by
- 196
- References
- 126
- Citations by year
- 2026: 26 · 2025: 35 · 2024: 44 · 2023: 40 · 2022: 27 · 2021: 22 · 2020: 2
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nanomaterials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Sabanci University (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- SUNUM (I.A.SN-19-00005 (S.C.) and I.A.SN-19-00001 (A.Z.))
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- niosomes, ocular drug delivery, nonionic surfactants, nanocarriers, eye diseases, drug loading and release, niosome characterization, topical ocular administration, drug bioavailability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.